Canada issues warning about unlicensed sex drugs

Fri May 23, 2008 12:50pm EDT
 
[-] Text [+]

OTTAWA (Reuters) - Canadians should avoid unlicensed drugs that claim to improve sexual performance because they could cause problems such as loss of consciousness, prolonged erections and chest pain, the health ministry said on Friday.

Health Canada issued the warning in a release about a product called Desire, which was found to contain the prescription drug phentolamine -- something not indicated on the label.

"Health Canada advises consumers not to use Desire or any other unauthorized products promoted to increase sexual performance that are advertised as 'all natural', as such products may contain undeclared prescription drugs that may pose serious risks to health," it said in a statement.

Phentolamine is used in the prevention and control of high blood pressure in patients with adrenal tumors.

"Use of phentolamine by patients with heart disease can potentially result in serious cardiac side-effects such as low blood pressure, chest pain and abnormal heartbeat," said Health Canada.

"Other side-effects may include dizziness, loss of consciousness, prolonged erection, headache, flushing, nasal congestion, indigestion and abdominal pain."

Health Canada said it was taking steps to ensure Desire -- which it said could be on sale across Canada and over the Internet -- was removed from the marketplace.

(Reporting by David Ljunggren; editing by Rob Wilson)

 
Dr. Qurrath U. Ain of the Elmhurst Pediatric Emergency Center examines a patient with flu-like symptoms at Elmhurst Hospital in New York in this December 12, 2003. file photo. REUTERS/Shannon Stapleton/Files
Healthcare Reform

Reuters provides an in-depth look at the issues facing Americans as the Obama administration wrestles with healthcare policy.  Full Coverage 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A pharmacist holds bottles of the prescription arthritis and pain medication VIOXX at a New York City Pharmacy after manufacturer Merc Research Laboratories announced a worldwide voluntary withdrawal of the drug September 30, 2004
Risky negotiations

While the government may be able to negotiate prescription cost-savings up front, the long term effect would hurt pharmaceutical innovation, writes Peter J. Pitts   Commentary | Full Coverage 

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better